You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

404 Results
Document
Aug 2022
Document
Aug 2022
Document
Nov 2022
Document
Nov 2022
Document
Nov 2022
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal, 
Small bowel and appendix
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    encorafenib - In combination with cetuximab or panitumumab in previously treated BRAF V600E-mutated metastatic colorectal cancer, according to clinical criteria
New Drug Funding Program
    Panitumumab - In Combination with Encorafenib for Previously Treated Metastatic Colorectal Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
encorafenib,
PANitumumab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Apr 2024
Document
Dec 2022
Document
Dec 2022
Document
Dec 2022
Guidelines and Advice
Status: Current
ID: PET 2022-1
Jan 2023
Document
Jan 2023
Document
Jan 2023

Pages